糖尿病治療薬の世界市場-2023年～2030年

市場概要

糖尿病治療薬の世界市場は、2022年に6,140万米ドルに達し、2030年には1億620万米ドルに達する大きな成長が予測されています。糖尿病治療薬の世界市場は、2023～2030年の予測期間中に7.2%のCAGRを示すと予測されています。

糖尿病は、世界各国に大きな社会的・経済的ジレンマを引き起こしている蔓延病として注目を集めています。科学の進歩、ヘルスケア施設の充実、識字率の向上にもかかわらず、この病気は依然として多くの人々、特に中低所得国に影響を及ぼしています。

市場力学

糖尿病管理の増加が予測期間中の世界糖尿病治療薬市場の成長を後押し

米国の糖尿病研究開発は、インスリン産生細胞を保護バリア内に封じ込めた生体工学的ミニ臓器を開発しています。このミニ膵臓は、腹膜の一部であるオメンチンに移植されます。

2023年4月、Glooko, Inc.は、ヘルスケア専門家と患者が使用するGlookoの糖尿病管理用プラットフォームに同社の技術を含めるため、ヘルスケアとの新たな世界協力を発表しました。連携ケア、遠隔患者モニタリング、デジタル治療技術を組み合わせることで、相互運用可能なソリューションを提供し、ボーラスインスリンの投与量に関するガイダンスを必要とする1型および2型糖尿病患者へのアクセスを改善します。

主要企業間の連携が世界の糖尿病治療薬市場に成長機会をもたらす

大量生産に絶好の機会を提供する技術の進歩とオンラインプラットフォームによるリーチの拡大が市場の競争力を高めています。主な市場プレイヤーは、Novo Nordisk、AstraZeneca、Pfizer、Abbott India Ltd、Eli Lilly、AbbVie Inc.、Dr. Reddy`s Labs、Sanofi、Novartis International、Merck、Boehringer Ingelheimなどです。

例えば、2022年2月、包括的な糖尿病管理ケアの新時代を切り開くために、ヘルスケアの世界的リーダーであるアボットは、重要なヘルステック・パートナーであるBeatOとSugar.fit、PharmEasy、GOQii、1MG、Zyla Health、HealthifyMe、Fitterflyとの新たなパートナーシップを発表しました。

Abbott hopes社は、これらのパートナーシップを通じて800万人の糖尿病患者を獲得したいと考えており、そのうち650万人はPharmEasyと1MGを通じてこれらのソリューションにアクセスできます。遠隔相談、糖尿病患者に特化したコーチング、食事計画とともに、この事業は効果的なグルコースレベルの維持に重点を置いています。

COVID-19影響分析

COVID-19の流行は糖尿病治療薬市場に大きな影響を与えました。パンデミックの間、ケアの継続性を維持するために遠隔医療サービスが急速に拡大しました。ヘルスケア専門家は、遠隔医療のおかげで、糖尿病患者の遠隔治療、バーチャル診察、薬の処方が可能になっています。糖尿病治療へのアクセスのしやすさと利用可能性は、遠隔医療の利用の高まりから恩恵を受けています。

ロシア・ウクライナ紛争分析

ロシア・ウクライナ紛争が糖尿病治療薬市場に与える影響は、複雑かつ多面的です。紛争は影響を受けた地域の研究開発業務に影響を与える可能性があります。科学機関の混乱は、糖尿病治療法の開発を目的とした研究開発活動を妨げ、資金調達の減少や、熟練した研究者や医療従事者の移住による頭脳流出を引き起こす可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 糖尿病有病率の増加
  • 抑制要因
    • 糖尿病治療薬に伴う副作用
  • 機会
    • 技術の進歩
  • 影響分析

第5章 産業分析

• ポーターの5フォース分析
• サプライチェーン分析
• アンメットニーズ
• 規制分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 人工知能分析

第9章 タイプ別

• 1型糖尿病
• 2型糖尿病
• 妊娠糖尿病

第10章 治療タイプ別

• 経口糖尿病治療薬
• 注射糖尿病治療薬
• その他

第11章 エンドユーザー別

• 病院・診療所
• 在宅医療
• その他

第12章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ

第13章 競合情勢

• 競合シナリオ
• 製品ベンチマーク
• 企業シェア分析
• 主な発展と戦略

第14章 企業プロファイル

• Abbott India Ltd
  • 企業概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Novo Nordisk
• AstraZeneca
• Pfizer
• Eli Lilly
• Dr. Reddy`s Labs
• Sanofi
• Novartis International
• Merck
• Boehringer Ingelheim

第15章 企業概要付録

Market Overview

The Global Diabetes Therapeutics Market reached US$ 61.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 106.2 million by 2030. The Global Diabetes Therapeutics Market is expected to exhibit a CAGR of 7.2% during the forecast period 2023-2030.

Diabetes draws attention to a spreading disease that is causing a significant social and economic dilemma in nations worldwide. Despite scientific advancements, greater healthcare facilities, and increased literacy rates, the disease still affects many people, especially in middle- and low-income nations.

Market Dynamics

Increasing Diabetes Management is Boosting the Global Diabetes Therapeutics Market Growth During the Forecast Period

The increased research for alternative treatment options is driving the global market, such as Diabetes Research Institute in the US, which is developing a bioengineered mini-organ where insulin-producing cells are encapsulated within a protective barrier. This mini-pancreas is implanted into the omentin, a part of the abdominal lining.

In April 2023, Glooko, Inc. announced a new global cooperation with Hedia to include its technology in Glooko's platforms for diabetes management used by healthcare professionals and patients. By combining linked care, remote patient monitoring, and digital therapeutic technologies, the cooperation will offer an interoperable solution that will improve access for patients with Type 1 and Type 2 diabetes who need guidance on how much bolus insulin to administer.

Collaboration Among Key Players Provides the Global Diabetes Therapeutics Market Growth Opportunities

Technological advances that provide excellent opportunities for high-volume manufacturing and increased reach through online platforms have made the market competitive. Major market players are Novo Nordisk, AstraZeneca, Pfizer, Abbott India Ltd, Eli Lilly, AbbVie Inc., Dr. Reddy`s Labs, Sanofi, Novartis International, Merck, Boehringer Ingelheim and others.

For instance, in February 2022, To usher in a new era of comprehensive diabetes management care, Abbott, the world leader in healthcare, announced new partnerships with important health-tech partners BeatO and Sugar. fit, PharmEasy, GOQii, 1MG, Zyla Health, HealthifyMe, and Fitterfly.

Abbott hopes to reach 8 million people with diabetes through these partnerships, 6.5 million of whom can access these solutions through PharmEasy and 1MG. Along with remote consultations, coaching tailored specifically for people with diabetes, and meal planning, the business focuses on maintaining an effective glucose level.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the diabetes therapeutics market. Telemedicine services were rapidly expanded to preserve the continuity of care during the pandemic. Healthcare professionals could treat diabetes patients remotely, have virtual consultations, and prescribe medication thanks to telemedicine. The accessibility and availability of diabetic treatments have benefited from the rising use of telemedicine.

Russia-Ukraine Conflict Analysis

The impact of the Russia-Ukraine war on the diabetes therapeutics market is complex and multifaceted. The conflict may impact research and development operations in the affected regions. Disruptions to scientific institutions may hamper research and development activities aimed at developing diabetic therapies, decreased financing, or brain drain caused by the emigration of skilled researchers and medical personnel.

Segment Analysis

The Global Diabetes Therapeutics Market is segmented based on type, therapy type, end-user, and region.

The Injectable Antidiabetics Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The injectable antidiabetics segment accounted for the highest market stake accounting for approximately 34.7% of the diabetes therapeutics market in 2022. Injectable antidiabetics, commonly referred to as injectable diabetes treatments, are drugs that are given intravenously to people with diabetes in order to monitor and control their blood sugar levels. People with type 1 diabetes, type 2 diabetes that is not well controlled with oral drugs, or people who need insulin therapy often use these medications. Insulin is the primary injectable antidiabetic medication used to manage diabetes. It is a hormone that helps regulate blood sugar levels.

Geographical Analysis

Increasing Collaborations And Partnerships Among the Key Players and Advancement in Diabetes Therapeutics Dominate the North American Region

North America is expected to dominate the diabetes therapeutics market, accounting for around 37.6%. For instance, in April 2022, Positive findings from Better Therapeutics' recently finished pivotal study for BT-001, a prescription digital treatment that would be the first of its kind for those with type 2 diabetes, were released.

According to its manufacturer, one of the most prevalent and expensive chronic diseases in the US is to be improved by a new prescription digital treatment. The company claims that over six months, improvements in A1c levels were sustained due to its cognitive-behavioral therapy-focused solution.

Competitive Landscape

The major global players in the market include: Abbott India Ltd, Novo Nordisk, AstraZeneca, Pfizer, Eli Lilly, Dr. Reddy`s Labs, Sanofi, Novartis International, Merck, and Boehringer Ingelheim among others.

Why Purchase the Report?

• To visualize the Global Diabetes Therapeutics Market segmentation based on the type, therapy type, end-user, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of diabetes therapeutics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Diabetes Therapeutics Market Report Would Provide Approximately 61 Tables, 57 Figures And 195 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Therapy Type
• 3.3. Snippet by End-user
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing prevalence of diabetes
  • 4.1.2. Restraints
    • 4.1.2.1. Side effects associated with diabetes therapeutics
  • 4.1.3. Opportunity
    • 4.1.3.1. Technological advancements
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Type

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.1.2. Market Attractiveness Index, By Type
• 9.2. Type 1 Diabetes*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Type 2 Diabetes
• 9.4. Gestational Diabetes

10. By Therapy Type

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 10.1.2. Market Attractiveness Index, By Therapy Type
• 10.2. Oral Antidiabetics*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Injectable Antidiabetics
• 10.4. Others

11. By End-user

• 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
• 11.1.2. Market Attractiveness Index, By End-user
• 11.2. Hospitals and Clinics*
  • 11.2.1. Introduction
  • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 11.3. Homecare
• 11.4. Others

12. By Region

• 12.1. Introduction
  • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 12.1.2. Market Attractiveness Index, By Region
• 12.2. North America
  • 12.2.1. Introduction
  • 12.2.2. Key Region-Specific Dynamics
  • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.2.6.1. The U.S.
    • 12.2.6.2. Canada
    • 12.2.6.3. Mexico
• 12.3. Europe
  • 12.3.1. Introduction
  • 12.3.2. Key Region-Specific Dynamics
  • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.3.6.1. Germany
    • 12.3.6.2. The U.K.
    • 12.3.6.3. France
    • 12.3.6.4. Italy
    • 12.3.6.5. Spain
    • 12.3.6.6. Rest of Europe
• 12.4. South America
  • 12.4.1. Introduction
  • 12.4.2. Key Region-Specific Dynamics
  • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.4.6.1. Brazil
    • 12.4.6.2. Argentina
    • 12.4.6.3. Rest of South America
• 12.5. Asia-Pacific
  • 12.5.1. Introduction
  • 12.5.2. Key Region-Specific Dynamics
  • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.5.6.1. China
    • 12.5.6.2. India
    • 12.5.6.3. Japan
    • 12.5.6.4. Australia
    • 12.5.6.5. Rest of Asia-Pacific
• 12.6. Middle East and Africa
  • 12.6.1. Introduction
  • 12.6.2. Key Region-Specific Dynamics
  • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

13. Competitive Landscape

• 13.1. Competitive Scenario
• 13.2. Product Benchmarking
• 13.3. Company Share Analysis
• 13.4. Key Developments and Strategies

14. Company Profiles

• 14.1. Abbott India Ltd*
  • 14.1.1. Company Overview
  • 14.1.2. Product Portfolio and Description
  • 14.1.3. Financial Overview
  • 14.1.4. Key Developments
• 14.2. Novo Nordisk
• 14.3. AstraZeneca
• 14.4. Pfizer
• 14.5. Eli Lilly
• 14.6. Dr. Reddy`s Labs
• 14.7. Sanofi
• 14.8. Novartis International
• 14.9. Merck
• 14.10. Boehringer Ingelheim

LIST NOT EXHAUSTIVE

15. Appendix

• 15.1. About Us and Services
• 15.2. Contact Us